Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Time-Scale Target Parameters and Two-Step Estimation in Longitudinal Trials for Progressive Diseases.

Statistics in medicine·2026
Same author

Handling Missing Data in Participants with Baseline but No Post-Baseline Data.

Pharmaceutical statistics·2026
Same author

Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease.

The journal of prevention of Alzheimer's disease·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Garrett B Duncan1, Tyler M Duke1, Samuel B Johnson1

  • 1Pentara Corporation, Salt Lake City, UT, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

化化 (pTau) 生物标志物在预测阿尔茨海默病 (AD) 进展方面,其准确性与昂贵的粉样蛋白PET扫描相美. 这些方便的血液测试提供了更高的灵敏度,并可以实现更小,更具成本效益的临床试验.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

科学领域:

  • 神经学 神经学
  • 生物标志物发现发现
  • 阿尔茨海默氏症疾病研究研究

背景情况:

  • 阿尔茨海默病 (AD) 病理生理学和生物标志物研究正在取得进展.
  • 粉样PET是AD试验中的标准诊断工具和结果指标,但它昂贵且资源密集.
  • 化的 (pTau) 正在作为一种更容易获得的AD生物标志物进行研究.

研究的目的:

  • 在阿尔茨海默病 (AD) 试验中评估血pTau (pT217,pT181) 在预测临床结果和疾病进展方面的准确性和灵敏性.
  • 为了比较血pTau生物标志物的实用性与传统的粉样蛋白PET成像.
  • 评估血pTau的潜力,作为药物开发早期阶段的主要结果衡量标准.

主要方法:

  • 来自抗粉样单克隆抗体 (mAb) 研究的已公布数据的分析.
  • 计算等离子体pT217/pT181治疗效果与临床结果之间的小组级皮尔森相关性.
  • 血pTau相关性与粉样PET相关性的比较.
  • 用于模拟概念验证研究设计和评估样本大小要求的功率计算.

主要成果:

  • 血pT217和pT181显示了与粉样PET相比的临床结果的组级相关性.
  • 血pT217/pT181的效应大小 (科恩的d) 比标准临床结果评估 (ADAS-Cog,ADCS-ADL,CDR-SB) 的效应大.
  • 血pT217/pT181对疾病进展的敏感性增加了3倍,在样本大小的九分之一的情况下实现了可比功率.

结论:

  • 血pTau生物标志物 (pT217,pT181) 为预测AD的临床结果提供了一个可靠,具有成本效益和可访问的替代品,而不是粉样蛋白PET.
  • 与当前的临床测量相比,这些生物标志物表现出更大的效果大小和更高的疾病进展敏感性.
  • 血pTau生物标志物可以促进更小,更有效的阿尔茨海默病药物开发早期临床试验.